Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D'Ambrosio, Lorenzo;Touati, Nathan;Blay, Jean-Yves;Grignani, Giovanni;European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group;et.al.
(2020) Cancer — Vol. 126, n° 11, p. 2637-2647 (2020)

Files

2020_D_Ambrosio_Cancer.pdf
  • Open Access
  • Adobe PDF
  • 4.41 MB
Download

Details

Authors
  • D'Ambrosio, Lorenzoorcid-logo
    Author
  • Touati, Nathan
    Author
  • Blay, Jean-Yvesorcid-logo
    Author
  • Grignani, Giovanniorcid-logo
    Author
  • Mazzeo, FilomenaUCLouvain
    Author
  • European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Collaborator
Show more
Abstract
BACKGROUND: The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first-line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) sites. METHODS: The inclusion criteria were a confirmed histological diagnosis, treatment between January 2010 and December 2015, measurable disease (Response Evaluation Criteria in Solid Tumors 1.1), an Eastern Cooperative Oncology Group performance status ≤2, and an age ≥ 18 years. The endpoints were progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). PFS was analyzed with methods for interval-censored data. Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for histology, grade, age, sex, performance status, tumor site, and tumor extent. RESULTS: Three hundred three patients from 18 EORTC-STBSG sites were identified. One hundred seventeen (39%) received doxorubicin plus dacarbazine, 71 (23%) received doxorubicin plus ifosfamide, and 115 (38%) received doxorubicin. In the 2:1:2 propensity score-matched population (205 patients), the estimated median PFS was 9.2 months (95% confidence interval [CI], 5.2-9.7 months), 8.2 months (95% CI, 5.2-10.1 months), and 4.8 months (95% CI, 2.3-6.0 months) with ORRs of 30.9%, 19.5%, and 25.6% for doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer with doxorubicin plus dacarbazine versus doxorubicin (hazard ratio [HR], 0.72; 95% CI, 0.52-0.99). Doxorubicin plus dacarbazine was associated with longer OS (median, 36.8 months; 95% CI, 27.9-47.2 months) in comparison with both doxorubicin plus ifosfamide (median, 21.9 months; 95% CI, 16.7-33.4 months; HR, 0.65; 95% CI, 0.40-1.06) and doxorubicin (median, 30.3 months; 95% CI, 21.0-36.3 months; HR, 0.66; 95% CI, 0.43-0.99). Adjusted analyses retained an effect for PFS but not for OS. None of the factors selected for multivariate analysis had a significant interaction with the received treatment for both PFS and OS. CONCLUSIONS: This is the largest retrospective study of first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

D’Ambrosio, L., Touati, N., Blay, J.-Y., Grignani, G., Flippot, R., Czarnecka, A. M., Piperno-Neumann, S., Martin-Broto, J., Sanfilippo, R., Katz, D., Duffaud, F., Vincenzi, B., Stark, D. P., Mazzeo, F., Tuchscherer, A., Chevreau, C., Sherriff, J., Estival, A., Litière, S., et al. (2020). Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer, 126(11), 2637-2647. https://doi.org/10.1002/cncr.32795 (Original work published 2020)